Competitive pipeline tracking, explained.

What tracking a rival's pipeline means: finding out what changed, and whether it touches your plan

The five stages of a rival move, from a public edit to a decision on your program

1. A rival actsA first patient is dosed, a site opens, a date slips, a filing is accepted.
2. The act surfaces in publicIn a registry record, a pipeline page, a call, an abstract or an agency database, days or months later.
3. Someone finds it and checks itCompare against the last copy, merge duplicates, confirm the source. This step is the subject of this guide.
4. Someone says what it meansA short written view for one program team, with an owner for each action.
5. Your plan changes, or holdsA trial design, a site list, a comparator, a deal, a stop.

Step 3 is where most of the hours go, and step 4 is where most of the value lies.

Things that surprise people about competitor drug tracking

The words on a competitive landscape: readout, primary completion, top-line and watch list

Fourteen terms are defined on the summary page.

Registries, company pages, investor calls, congress abstracts and agency databases each answer a different question

In shortAlmost everything in a defensible landscape comes from five public families of source. Only registries run on a legal clock. Company statements come fastest and leave most out. Agency databases are the closest to final. No single source answers all four questions, which is why a landscape built on one of them has holes.

The registry you read depends on where the rival runs its trials

ClinicalTrials.gov held 610,050 records on November 3, 2026, the public interface reports.1 It is the largest source, and it is still only one. The World Health Organization lists 18 primary registries in its network, among them the EU's CTIS, Japan's jRCT, China's ChiCTR, Korea's CRiS and India's CTRI, and it says each meets criteria for content, quality and validity.18 A rival running its first trials in Japan or China can be invisible on a watch list built only from the US record.

In the European Union, the Clinical Trials Information System, or CTIS, has run under revised transparency rules since June 18, 2024. Its information must be public unless an exemption applies, such as personal data or commercially confidential information, and the portal shows items such as the EU trial number, the sponsor and the start and end dates of recruitment.7

The ClinicalTrials.gov update rules: 21 days to register, 30 days for real events, 12 months for everything else

In short42 CFR Part 11 sets deadlines field by field. Fields that mark a real event, such as first patient, a site opening or a trial stopping, carry 30-day clocks. Plans do not. So a status change tells you something happened recently, and an unchanged estimate tells you very little.

Read the rule as an intelligence problem and it tells you where to look. Study start date, overall recruitment status, individual site status, and the actual primary and study completion dates each have a 30-day duty, and a status of suspended, terminated or withdrawn must come with a stated reason.2 These are the fields worth comparing week by week.

The same section says most other registration information must be updated "not less than once every 12 months".2 An estimated completion date is in that group until the trial actually reaches it. A sponsor that re-plans a readout may have up to a year before the record has to agree, unless the plan changes through a protocol amendment that is communicated to participants, which carries its own 30-day duty.

The trials the US registry rule leaves out, which become blind spots on a landscape

The rule requires four things together for a drug trial: it is interventional (participants are assigned a treatment), its phase is other than phase 1, it studies an FDA-regulated product, and it has a US link such as a US site or a US investigational new drug application.11 So three kinds of program can be missing with no one breaking a rule:

1. First-in-human work. Phase 1 falls outside the requirement, though many sponsors list voluntarily. Our count shows 30,391 industry-led phase 1 records on the site, leaving out combined phase 1/2 records.1
2. Trials with no US link. A trial run entirely abroad may sit only on a national registry.18
3. Non-interventional studies. Observational work that may hint at a sponsor's next move.

How much enforcement stands behind a registry date

Do not treat the clocks as a guarantee. In a widely cited audit, 40.9% of 4,209 trials due to report did so within the one-year deadline, and 63.8% had submitted at any time, as of September 2019; industry sponsors did better than other non-government sponsors.21 FDA's list of Notices of Noncompliance holds 11 letters from April 2021 to October 2026, three of them dated October 2026.22

How early rival trials appear on ClinicalTrials.gov, and how stale their planned dates get: our count

In shortWe counted, using the registry's public data on November 3, 2026. Seven in ten industry trials that started in 2024 were visible before their first patient. Among open trials with an estimated finish date, about one in six shows a date already in the past. A record is good early warning and a weak clock.

Two things follow. If you compare records weekly, you will usually see a rival trial before its first patient, often with planned sites and enrollment attached. And a delay sits between the sponsor and you: first submission to first posting took a median of 7 days in this group, and 26 days at the 90th percentile.1 The first public sign of an event therefore lags the event by days or weeks, even when everyone is on time.

You can measure your own: each ClinicalTrials.gov record links to its earlier versions through History of Changes.24 Take 30 rival trials that have finished and compare the first estimate with the actual date.

The number of trials to read keeps rising: industry Phase 2 and Phase 3 starts by year

A single indication is small and lumpy by comparison. Trials listing psoriasis as a condition ran from 17 to 48 starts a year over the same ten years, on the same count.1 That is the size of the job for one watch list: a few dozen new records a year, and every existing record to re-read.

Primary completion, study completion and top-line: why a rival's readout date is an estimate built on an estimate

In shortCount a readout from primary completion, and check whether the date is marked estimated or actual. The study completion date can sit a year or more later. Then write down what kind of date you hold, because guidance, a congress slot, a goal date and a registry estimate deserve different trust.

The rule defines the completion date, which it also calls the primary completion date, as the date the final subject was examined or treated "for the purposes of final collection of data for the primary outcome", whether the trial finished as planned or was terminated.25 The study completion date adds secondary outcomes and adverse events, up to the last visit.25

A Phase 3 trial with a main measure at week 16 and a year of follow-up after it can report long before it finishes. An analyst who counts from study completion is about a year late.

Every date is labeled estimated or actual. An estimate is the sponsor's plan. Once the trial reaches it, the sponsor must change the date to actual within 30 days and give the actual enrollment.2 That change is itself worth catching: when a date flips to actual, the data exist. The sponsor knows soon after, and the one-year results clock has begun.20

Working a readout estimate through, with the fictional numbers from the example

PDUFA date meaning: a goal measured from the 60-day filing date, which FDA can beat, miss or answer with a refusal

In shortThe PDUFA date, named for the Prescription Drug User Fee Act, is FDA's performance goal for one review. It is 10 or 6 months from the 60-day filing date for a new molecular entity or an original biologic. Meeting it means FDA acted, and the action can be a complete response letter, which says FDA cannot approve the application yet. FDA began publishing those letters in 2025 and paused prompt release of new ones in April 2026. A voucher pilot aims for reviews far shorter than the standard clock.

The commitment letter states the goals as portfolio targets: review and act on 90 percent of standard new molecular entity applications and original biologics applications "within 10 months of the 60-day filing date", and 90 percent of priority ones within 6 months.8 A new molecular entity is, broadly, a drug whose active part FDA has not approved before.26 The filing date marks the end of the 60 days FDA has to decide whether an application can be filed.27

Worked through with an invented filing: an application submitted on January 15, 2026 reaches its 60-day filing date on March 16, 2026. The standard goal is then January 16, 2027, and the priority goal is September 16, 2026.

In practice the date usually becomes public when the company says so, since FDA's rule keeps an unapproved application's existence confidential unless it is already public.3 A proposed change to that rule is below. Keep the wording: "target action date" is a company's statement of an agency goal, and it can surprise you in two ways: the action can be a complete response letter, and it can come months early.

What changed on rival decision calendars from 2025 to 2027

For a tracker this means four things:

1. A filing acceptance no longer tells you how long you have, since FDA can act far ahead of the goal date.
2. A rival's failed review may be readable in FDA's words, redacted, in the openFDA dataset, where earlier you usually had only the company's account.17 Do not rely on its timing, though. A spokesperson for the US health department (HHS) told a trade publication the effort was temporarily paused from April 2026 after a citizen petition, and new letters appeared again that July.31,34 On November 3, 2026 the dataset held 458 letters, last updated August 13, 2026, the newest dated August 7.35
3. The release rule may change again. A proposed rule to widen the Commissioner's discretion to release such letters, and to drop the presumption that an application's existence is confidential, was scheduled for October 2026; we found none published by November 3.36
4. A voucher in a rival's hands is a date risk worth its own row, since FDA's page lists award rounds through April 24, 2026.30

Europe works differently. EMA publishes a monthly list of medicines the Committee for Medicinal Products for Human Use is evaluating, with the common name of the active substance and a short summary of the indication, and it adds separate files for extensions of indication.16 The October 2026 list was first published on October 9, 2026.16 A company's name may not be on it, so a tracker must match by substance.

What top-line results and congress abstracts leave out, and how to read a rival's clinical trial results

In shortA top-line release is evidence that a statement was made. When a release comes at least 90 days before the paper, the median gap is about eight months, and the release may be the only account there is. Keep the exact sentence, note what it omits, and let the abstract and the paper correct it. Rival tolerability numbers are clinical trial results and belong in the same table, read with the same care.

A form to fill in when a rival reports: claim, source, what is missing

Comparing two rival trials side by side is a judgment and should say so

Two trials in adjacent columns invite a head-to-head reading, yet each ran on its own patients with its own control group. Take the fictional abstract later in this guide: median progression-free survival (the time until the disease worsened or the patient died37) of 11.0 against 7.2 months, a hazard ratio of 0.64. A hazard ratio below 1 means fewer events on the new treatment, and within that trial the gap is 3.8 months, our arithmetic.

Set beside another trial with different patients, a different control arm and different follow-up, those numbers show a difference in trials as much as a difference in drugs. Copy the numbers exactly, say so whenever you compute a number the source did not report, and label any cross-trial view as your own reading.

Public sources and insider information: what a competitive intelligence team may read, and what it must walk away from

In shortReading what a rival has published is lawful and is the basis of the profession. Getting information by misrepresentation, or from someone breaking a duty of confidence, is not. Unpublished trial results of a listed company are also inside information, and a team that receives them has a securities problem as well as an ethics one. Write the limit down. Ask your counsel about your own case.

The profession's code, from the Strategic Consortium of Intelligence Professionals, is a set of guidelines for setting your own standards. Its seven principles include complying with all applicable laws and disclosing "one's identity and organization" before all interviews.38 Law sits underneath it. US trade secret law treats theft, bribery, misrepresentation, breach of a duty to maintain secrecy and inducing such a breach as improper means, and it carves out reverse engineering, independent derivation and other lawful means.5 Theft of a trade secret is a federal crime.39

Securities law adds a second limit, because a trial result can move a share price. Under US Regulation FD, when a listed company gives material nonpublic information (important news not yet released) to certain market participants, it must make that information public, at once if the disclosure was intentional and promptly if it was not; people who owe a duty of confidence or who agree to confidentiality are excluded.13 That is one reason news comes out on public calls and in filings.

In the EU, inside information is information of a precise nature, not yet public, that would be likely to significantly affect the price of a financial instrument, and unlawful disclosure is banned along with insider dealing.40

Competition law: why you read about rivals and never talk to them about plans

The US antitrust agencies withdrew their guidelines on collaboration among competitors on December 11, 2024 and pointed businesses to statutes and case law.44 They asked for comment on possible new guidance on February 23, 2026, and we found none issued by November 3, 2026.45

A 2018 staff note from the Federal Trade Commission (FTC) on pre-merger diligence still gives a plain list of what is sensitive between competitors, "current and future price information, strategic plans, and costs", and says clean teams, the select people allowed to see a counterparty's sensitive data in a deal, should not include people responsible for competitive planning, pricing or strategy.43 That note concerns merger talks, and the logic carries over: public reading is one-way. A conversation with a rival about what either of you plans is a different act.

The written limit a CI policy should carry

1. A closed list of source families the team may read, with paid sources named.
2. A ban on pretexting (posing as someone else to get information), undisclosed interviews, and asking site staff or former employees about unreported data.
3. A named lawyer or compliance officer who hears any unexpected disclosure the same day, and a rule to stop, and to neither forward nor circulate it.
4. Controlled readership for your own plan dates, which may be inside information about your own company.
5. The source kept with every claim, which is what makes the other four provable a year later.

Competitive enrollment: a rival's site list can tell you which of your shortlisted hospitals are about to split their patients

In shortTwo trials recruiting the same patients at one hospital compete for a limited pool. Registries list facilities and each site's status, and the status has a 30-day update clock. Setting a rival's list against your shortlist is cheap, and few teams do it after the site list is approved.

A 2014 cost review for the US health department put the barrier plainly: "There is competition for limited patient pools for certain conditions, such as rare cancers and multiple sclerosis", and sites "are often selected based on the location of investigators rather than patients".47 No published figure says how much of a site's shortfall comes from a rival trial. Your own data can show it: compare enrollment at shortlisted sites where a rival opened with those where none did.

Our count: how often psoriasis trial sites are shared between sponsors

Late-stage trials are wide enough for the check to matter. Industry Phase 3 trials that started in 2024, counting combined Phase 2/3, listed a median of 19 sites, a quarter listed 74 or more, and 46% ran in two or more countries, on the same count.1 Those numbers come from public records and would take an analyst hours per trial to compare by hand.

Ten errors that make a pharma competitive landscape wrong, and why careful people make them

In shortMost errors come from three habits: reading a plan as a fact, losing the sentence a claim came from, and checking too rarely. Those habits grow from hand work under time pressure, and no regulator inspects this work, so nothing catches them.

Why hand-built drug landscapes are breaking: about 23,000 drugs in development, and CI leaders who expect no more people to do the reading

In shortThe pipeline is large and may have stopped growing, depending on who counts. Most assets on any board will never reach approval, so a board needs pruning as well as adding. Most CI leaders expect flat or lower budgets and headcount. No public figure sizes the pharma CI market itself.

Read that funnel as a warning about attention. Phase II is the largest hurdle, with 28.9% moving on.49 A board that gives every early rival a row will fill with assets that quietly stop, and sponsors have a 30-day duty to report a stopped status only for trials the rule covers.2,11

The other half of the problem is people and budget. Trinity Life Sciences reports that "the clinical-stage pipeline of new medicines more than doubled between 2019 and 2024", citing PMPRB and ISPOR 2025 data, and that "most pharma CI leaders expect flat or lower budgets and headcount over the next 12 months", citing TGaS Advisors surveys.51 That doubling uses a different count from Citeline's flat total, so treat neither as settled. Both point the same way for a CI team: more to read, and no more people to read it.

Pharma competitive intelligence with AI: what regulators say, and why outcome numbers still need a person

In shortComparing records, copying sentences and checking databases are repeatable, so they suit software. Measured accuracy is good on background facts and uneven on outcome numbers. Deciding what a change means is a judgment. The main AI rules for drug development were written for other uses, which leaves your own policy and evidence to carry the weight.

A useful test for what to automate: would a second competent person, given the same sources, produce the same output? Comparing two versions of a record passes. So does copying a hazard ratio from a table, if the copy is checked. Deciding whether a rival's Phase 3 start should change your own trial fails it, and the disagreement between two good people is the reason to have them.

Where the AI rules stand for competitive intelligence, as of November 3, 2026

Four limits a pipeline-reading system should state out loud

1. It reads public sources only, and it cannot know what a rival has not published. A quiet month on a board may mean nothing happened or nothing was said.
2. Copying accuracy needs a test on your own material, since one evaluation on sepsis trials does not transfer to oncology abstracts.
3. A confidence score is the system's view of itself. Keep a person on anything that will change a decision.
4. A forecast stays labeled as one, and a model's estimate of a rival's readout should never be written as a date.

Who builds a competitive landscape in pharma, where the analyst's week goes and how teams resource it

In shortA CI lead and a few analysts read five source families, build a deck, and take it to program teams monthly or quarterly. Most of the hours go to finding and checking. Teams buy a database, outsource to an agency, or read by hand, and most combine them.

Five colleagues around one rival move, and the question each one asks

Where a landscape refresh's hours go

Database, agency or reading in house: how pharma teams resource pipeline tracking

Wages give a rough floor for the cost of the reading. The broad US occupation closest to this work, Market Research Analysts and Marketing Specialists, had a median wage of $37.87 an hour in 2025, with about 952,700 people employed, which covers far more than pharma.56 A specialist oncology analyst earns more than that, so use your own loaded cost.

ORX-23 moves to Phase 3 on the psoriasis race board, with its first patient dosed October 3 and both sources one click away

In shortThis is the example from the top of the page, inside the product. Before anyone is at a desk, six specialist agents, pieces of software that each hold one job, read the public sources for five watch lists. Lena Ortiz, the competitive intelligence lead, opens a board that has already moved, checks each move against its source and decides what matters. The product reads public sources, and people decide what it means.

1

Four watchers read every source before anyone is in

At 6:00 am the weekly run starts on 5 watch lists and 49 assets. The Registry watcher checks 612 trial records and finds 18 changed. The News watcher reads 38 releases and pipeline pages and finds 9 relevant. The Abstract reader goes through 212 abstracts and matches one late-breaker, an abstract submitted after a congress's regular deadline.14 The Approval watcher finds one new US approval.

The Change detector merges 35 findings into 28 changes, 6 of them significant, and the run ends at 6:14 am across 1,284 sources.

2

The race board answers who is ahead of IM-7740

Each indication gets a lane. Every rival sits on its phase and your own program is the dark marker. Rows sort by phase and then by next readout, so anyone ahead of you reads from the top down.

In moderate-to-severe plaque psoriasis the header reads 5 ahead of IM-7740 and 6 of 7 read out before us. Beside the lanes, this week's three moves are listed with their sources.

3

One click shows ORX-23's move with the old and new text

Selecting ORX-23 opens its stage path, the move and a countdown: 18 months to primary completion in March 2028. A note says it shares IM-7740's mechanism, and its Phase 3 data are due before your own Phase 3 is planned to start, in the second quarter of 2028.

Both sources sit below: the registry change from version 2 to version 3, and the pipeline page capture. A reader can open either at the exact passage.

4

A readout moved a month earlier, in one sentence on a call

On an investor call on October 1, Quillon Therapeutics said enrollment finished early, so it now expects top-line data from QUILL-PSO-1 in December, ahead of its earlier guidance of January 2027. QLN-2319's countdown turns amber at 71 days, and the move is listed.

That sentence is the only public source for the new date. The product keeps it word for word, and the date stays labeled as guidance from the sponsor.

On NX-4127's board: a rival approval that changes the comparator, a first-line Phase 3 and 38 sites on your shortlist

In shortThe sponsor's second watch list follows an invented cancer target, ZK4. Three of this week's 11 changes matter to NX-4127, a Phase 2 drug in biliary tract cancer. First-line means a patient's first treatment, and second-line the one after it. The product shows what changed and proposes why it matters. Lena confirms, and a named analyst stays responsible for the view.

Before and after, field by field, for the VNT-224 approval

The change feed compares this morning's capture with last Monday's. Status moved from Under review (priority) to Approved in the United States; the indication and a label limited to test-selected patients, with overall survival (the time until death from any cause37) of 12.4 against 6.8 months, appear for the first time. The approval letter and the sponsor's release sit beside the change with the passage marked. The Change detector writes two sentences on why it matters, and Lena has confirmed it.

A mechanism and phase map of 14 watched ZK4 assets

The landscape places each asset by mechanism (how the drug works) against phase, with your own program in dark blue. This week: 11 changes, 3 significant. Rows below carry the lead indication, last change and a threat rating for your program.

The readout calendar: 59 dates, each with its source

The readouts page holds every expected readout, decision and data release across all boards, split by whether a rival falls before or after your own date. Three rival readouts fall in the next 90 days. Each row names its source type, so a congress session and a guided month look different.

A one-page brief for the ZK4-B team: 14 claims, each linked to its passage, and nothing sent until Lena approves

In shortThe Brief writer drafts one page per program team: a three-line summary, what changed, what it means with an owner for each action, and what to watch next. The checks sit beside it. A named analyst approves, and the name, the time and the sent version are kept.

1

The brief sits beside its sources

The week 40 ZK4 brief says three things up top: VNT-224 is approved, SLN-0582 is in Phase 3 in the first-line setting where NX-4127 plans its own Phase 3, and WXC-907 met its Phase 3 endpoint (progression-free survival hazard ratio 0.64).

Under each change is a "so what": VNT-224 becomes the likely comparator for any second-line trial of NX-4127, and 38 of SLN-0582's likely sites are on your feasibility shortlist. Priya Ranvelle is to review the second-line Phase 3 design before the November 2 governance meeting, and Jonas Harbeck is to check the 38 shared sites before site selection closes on October 30.

2

Approval names what is still open

Before sending, the screen says 2 changes still need Lena's confirmation, SLN-0582 and PLH-12, and that approving confirms them as written. It lists the 14 readers, from the program lead to clinical operations, regulatory and market access, and how the brief goes out.

Program leads read and ask questions. Only the CI lead or analyst edits and sends.

3

Sent, with its trail

The activity list records each step: the Change detector found 11 changes, the Brief writer drafted 14 claims, Lena confirmed 9 of 11, then the two others with the brief, and sent it to 14 people at 9:09 am.

Six reading jobs, one person who decides, the public sources in and the sourced brief out

In shortEach agent holds one narrow job and has a line it never crosses. A person confirms what is significant and approves what is sent. Watch lists, schedule, rules and sources are settings, and each change is saved as a new version on the audit trail.

The one job each pipeline tracking agent holds, and the line it never crosses

What goes in and what comes out of a weekly watch run

Where the sample's changes came from over 12 weeks, and the time they took

The dashboard reports the sample's last 12 weeks: 280 changes across 49 watched assets, 45 significant, 46 briefs sent. The by-hand baseline on this screen, 4 days to refresh and 9 days for a move to reach the team, is the sample's own 2025 workload. It is an illustration, and no public benchmark exists.

Your watch lists, your rules: settings a CI lead changes without a release

Watch lists carry their assets, program team, readers and approver. Runs go weekly, twice a week or daily. Delivery is on approval or at noon on Monday, and never before an analyst approves. Same-day alerts cover approvals and major readouts. The significance rules are approvals, filings and label changes; major readouts; phase advances; new trials in your indication; trials stopped; a primary completion date moving more than three months; and sites in your shortlist countries.

Systems a competitive pipeline tracking team plans around

Botminds is SOC 2 Type II audited and manages information security to ISO 27001. A competitive brief is usually not a GxP record. If yours feeds a regulated process, the controls here support your compliance, and your quality team decides what that use requires.

A trial designed against yesterday's comparator: the costs of hearing about a rival's move late

In shortAnalyst hours are the visible cost and the smallest. The large costs are decisions made on stale facts: a design that must change, a site list that must be redone, days lost on a trial. Published figures give you the price of a day. You can find your own lag in a week.

Ten past moves, ten claims and one site list: how to audit your own landscape

Losses from late rival news that stay off the spreadsheet

What sourced weekly tracking returns: hours you can count and trial days that carry most of the value

In shortOn realistic inputs, saved analyst time alone may not pay for software, especially if you move from monthly to weekly reading. The case rests on decisions made sooner. The calculator shows both and tells you how many trial days the software has to save to pay for itself.

Four levers for pipeline tracking, each with its formula

The pipeline tracking calculator

Formulas: hours today = lists × refreshes × hours. Hours with review = lists × 52 × review hours. Time saved = (today − with review) × hourly cost, never below zero. Trial days valued = days × cost per day. Days that pay = (cost − time saved) ÷ cost per day.

The $40,000 is Tufts' direct cost estimate for Phase II and III.57 The 6.4 hours is 32 hours across five lists, an estimate. The defaults are not results, and a day saved is hard to prove, so credit only days a program lead will sign for. The broad occupation's median wage is $37.87 an hour for 2025; the $85 assumes a specialist's loaded cost.56

Can your competitive intelligence team automate yet? Eight scored questions on watch lists, limits and approvers

In shortEight questions score 0 to 2, and the last is for reflection. The meter adds up your score as you go. A team becomes ready mostly through work outside any software: a written limit, your own dates in one place and a person with time to approve.

What a CI team should do at a score of 0 to 6, 7 to 11 or 12 to 16

Eleven questions for any pipeline tracking vendor, us included: sources, accuracy and the insider information line

In shortEleven questions, each answerable with evidence. Buyers often judge these tools on coverage in a demonstration, and a program team later judges them on whether it believed the findings. Ask with your counsel in the room, and ask us too.

Replay 13 past weeks of one watch list in a ten-week pilot, compare with what your team knew and decide on three numbers

In shortReplay beats a live trial, since you already know what happened. Pick one indication with real activity, freeze what your team knew at the time, run the tool over the same weeks, and score what it caught and what it invented.

1. Pick one watch list with at least ten rival assets and a program lead who will read the result.
2. Write today's answer by hand: what you knew 13 weeks ago, and when each thing reached the team.
3. Agree the limit with counsel: the source list, the readers, and what happens to anything unexpected.
4. Load your dates and rules, then replay the weeks, with an analyst confirming as they would in real use.
5. Decide with three numbers: moves caught, lag saved and claims that opened their source correctly.

Scoring the watch list replay: moves caught, lag, sourcing, numbers and false alarms

The first three rows are the numbers you decide on. The other three show what to fix before you roll out.

Questions on pharma competitive intelligence, trial registries, PDUFA dates and insider information

In shortEach answer stands alone. For your own case, ask your counsel.